Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.

Stellbrink, Hans-Jürgen

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. [electronic resource] - AIDS (London, England) Jul 2013 - 1771-8 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1473-5571

10.1097/QAD.0b013e3283612419 doi


Adult
Anti-HIV Agents--adverse effects
Antiretroviral Therapy, Highly Active--adverse effects
Female
HIV Infections--drug therapy
HIV-1--isolation & purification
Heterocyclic Compounds, 3-Ring--adverse effects
Humans
Male
Oxazines
Piperazines
Pyridones
RNA, Viral--blood
Single-Blind Method
Treatment Outcome
Viral Load